CURELUNG

Determining (epi)genetic therapeutic signatures for improving lung cancer prognosis

 Coordinatore FUNDACIO INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGE 

 Organization address address: AVENIDA GRAN VIA HOSPITALET 199-203
city: L'HOSPITALET DE LLOBREGAT
postcode: 8908

contact info
Titolo: Mrs.
Nome: Verónica
Cognome: Padial
Email: send email
Telefono: +34 93 260 7143
Fax: +34 93 260 7219

 Nazionalità Coordinatore Spain [ES]
 Sito del progetto http://www.curelung.eu/
 Totale costo 3˙849˙117 €
 EC contributo 2˙965˙749 €
 Programma FP7-HEALTH
Specific Programme "Cooperation": Health
 Code Call FP7-HEALTH-2010-two-stage
 Funding Scheme CP-FP
 Anno di inizio 2011
 Periodo (anno-mese-giorno) 2011-01-01   -   2014-06-30

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    FUNDACIO INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGE

 Organization address address: AVENIDA GRAN VIA HOSPITALET 199-203
city: L'HOSPITALET DE LLOBREGAT
postcode: 8908

contact info
Titolo: Mrs.
Nome: Verónica
Cognome: Padial
Email: send email
Telefono: +34 93 260 7143
Fax: +34 93 260 7219

ES (L'HOSPITALET DE LLOBREGAT) coordinator 798˙520.00
2    KLINIKUM DER UNIVERSITAET ZU KOELN

 Organization address address: Kerpener Strasse 62
city: KOELN
postcode: 50937

contact info
Titolo: Ms.
Nome: Jutta
Cognome: Landvogt
Email: send email
Telefono: 492215000000
Fax: 492215000000

DE (KOELN) participant 332˙380.20
3    THE UNIVERSITY OF LIVERPOOL

 Organization address address: Brownlow Hill, Foundation Building 765
city: LIVERPOOL
postcode: L69 7ZX

contact info
Titolo: Ms.
Nome: Veronica
Cognome: Shaw
Email: send email
Telefono: +44 151 794 8722
Fax: +44 151 794 8728

UK (LIVERPOOL) participant 298˙370.00
4    FUNDACION PARA LA INVESTIGACION MEDICA APLICADA FIMA

 Organization address address: AVENIDA DE PIO XII 55
city: PAMPLONA
postcode: 31008

contact info
Titolo: Dr.
Nome: Andrew
Cognome: Solomon
Email: send email
Telefono: 34948194700
Fax: 34948194718

ES (PAMPLONA) participant 280˙024.00
5    UNIVERSITE JOSEPH FOURIER GRENOBLE 1

 Organization address address: "Avenue Centrale, Domaine Universitaire 621"
city: GRENOBLE
postcode: 38041

contact info
Titolo: Ms.
Nome: Leslie
Cognome: Hollett
Email: send email
Telefono: +33 4 76514488
Fax: +33 4 76635956

FR (GRENOBLE) participant 279˙600.00
6    FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI

 Organization address address: Via Venezian 1
city: Milan
postcode: 20133

contact info
Titolo: Dr.
Nome: Antonio
Cognome: Cannarozzo
Email: send email
Telefono: 390224000000
Fax: 390224000000

IT (Milan) participant 279˙000.00
7    UNIVERSITA DEGLI STUDI DI TORINO

 Organization address address: Via Giuseppe Verdi 8
city: TORINO
postcode: 10124

contact info
Titolo: Prof.
Nome: Giorgio
Cognome: Scagliotti
Email: send email
Telefono: 390119000000
Fax: 390119000000

IT (TORINO) participant 200˙400.00
8    INSTITUT GUSTAVE ROUSSY

 Organization address address: Rue Camille Desmoulins 39
city: VILLEJUIF
postcode: 94805

contact info
Titolo: Mr.
Nome: Arnauld
Cognome: Forest
Email: send email
Telefono: +33 1 42116604
Fax: +33 1 42116160

FR (VILLEJUIF) participant 150˙000.00
9    Krzysztof Kucharczyk Techniki Elektroforetyczne Spzoo

 Organization address address: Dzieci Warszawy 31/20
city: Warszawa
postcode: 02-495

contact info
Titolo: Dr.
Nome: Krzysztof
Cognome: Kucharczyk
Email: send email
Telefono: +4822 6687147
Fax: +4822 668752

PL (Warszawa) participant 149˙370.00
10    MRC HOLLAND B.V.

 Organization address address: Willem Schoutenstraat 6
city: AMSTERDAM
postcode: 1057 DN

contact info
Titolo: Dr.
Nome: Jan
Cognome: Schouten
Email: send email
Telefono: 31204121126
Fax: 31204890365

NL (AMSTERDAM) participant 124˙965.00
11    MAX PLANCK GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V.

 Organization address address: Hofgartenstrasse 8
city: MUENCHEN
postcode: 80539

contact info
Titolo: Mr.
Nome: Juergen
Cognome: Baaske
Email: send email
Telefono: +49 221 4726 230
Fax: +49 221 4726 341

DE (MUENCHEN) participant 73˙119.82

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

alteration    methylation    tumor    lung    gene    expression    scc    pard    cohorts    epi    tumours    cell    groups    drugs    alterations    therapy    resistance    molecules    small    genes    efficacy    proteins    determine    molecular    cancer    served    curelung    markers    clinical    genetic    altered    lc    epigenetic    treatment    sclc    therapeutic    scientists    tumors    prognosis    patients    profile    therapies    cells    frequency   

 Obiettivo del progetto (Objective)

'Lung cancer (LC) is still the most lethal type of cancer worldwide. The extremely poor prognosis for LC patients is partly due to the lack of effective therapies. At present, most patients with pulmonary carcinomas are treated with chemotherapy. This essentially consists of classic cytotoxic drugs which only improve survival in small cohorts in few cases. In spite of the rapidly growing understanding of the epigenetic and genetic profile of LC, such knowledge has contributed little to improving therapeutics. This scenario, however, is likely to change soon because several specific cancer therapies, targeting molecules that are altered in cancer, are being developed or are already undergoing clinical trials. Thinking ahead, our proposal focuses, on the one hand, on validating novel and specific therapeutic strategies, with particular emphasis on discovering (epi)genetic alterations that could act as novel targets for therapies, and, on the other, on defining the (epi)genetic markers that could determine the efficacy response or resistance to targeted therapies as well as the acquired resistance of the tumours to therapy. To reach our goals, we have designed an integrative and interdisciplinary approach involving leading European clinical scientists of international renown with prominent preclinical and basic research groups using high throughput and state-of-the art platforms for genomics and gene expression analysis. To date, no such comprehensive information exists. The results will be of great value for the stratification of lung tumours according to their genetic background for tailored treatments. The development of an (epi)genetic-based therapeutic prediction model will hopefully set the basis for future tailored treatment of LC as well as of other epithelial cancers.'

Introduzione (Teaser)

The advances in genome analysis technologies have geared cancer research towards novel paths of biomarker and therapeutic target discovery. A thorough omics analysis by the Curelung consortium aims to characterise the genetic profile of lung cancer and identify novel targets for therapy.

Descrizione progetto (Article)

Understanding cancer genomes has led to the design of targeted therapies against proteins altered in cancer cells, such as tyrosine kinase growth factor receptors. In the case of lung adenocarcinomas, mutated epidermal growth factor receptor (EGFR) proteins or translocations of ALK constitute targets that are currently being exploited therapeutically.

The EU-funded project 'Determining (epi)genetic therapeutic signatures for improving lung cancer prognosis' (Curelung) has emerged as the joint effort of leading European groups in the field of lung cancer to help define the genetic and epigenetic profile of this cancer type. By using state-of-the-art techniques, the consortium aims to identify novel targets and markers that will serve to personalise cancer treatment.

In the initial steps of the project, a genetic profile of alteration known cancer genes in lung cancer cells served to establish the profile, to define the frequency and to determine the accumulation in specific histopathological subtypes of each gene alteration. Further, the global gene expression and single nucleotide polymorphism (SNP) analysis unveiled the presence of inactivation at a novel tumor suppressor gene, PARD3, involved in cell polarity.

This molecular and genetic analysis was combined with histological evaluation of lung cancer samples from patient cohorts from different groups within the consortia. The overall frequency of PARD3 inactivating alterations was about ten percent of the tumors, most of them accumulating in the squamous cell carcinoma (SCC) subtype.

Furthermore, next-generation sequencing in lung primary tumors of the small cell lung cancer (SCLC), has served to identify recurrent mutations in histone-modifying genes (CREBBP, EP300 and MLL), among others involved in axon guidance and cellular migration.

These novel alterations found in lung SCC and SCLC are of great interest, since the genetics of these types of lung tumors are scarcely known.

On the other hand, methylation analysis points towards an overall hypermethylation or differential methylation pattern in lung cancer cells, indicating that gene silencing is a frequent event. The microRNA (miRNA) expression and splicing profiles have granted scientists with other means of predictive power that could be used to differentiate tumor from normal tissue.

Ongoing work towards the development of lung cancer models will aid the efficacy screening of various drugs. A library of 267 small organic molecules of diverse chemical classes is being tested for its potential to target several oncogenic signalling pathways and molecular targets.

Curelung partners are hopeful that the characterisation of (epi)genetic alterations in lung cancer will lead to improved diagnosis and novel therapeutic approaches.

Altri progetti dello stesso programma (FP7-HEALTH)

ARTFORCE (2011)

Adaptive and innovative Radiation Treatment FOR improving Cancer patients treatment outcomE

Read More  

PENTA-LABNET (2008)

Paediatric European Network Treatment AIDS Laboratory Network (PENTA LABNET)

Read More  

COUNTERSTROKE (2013)

Treating stroke with Affibody molecules targeting the inflammatory mediator HMGB1

Read More